Randomized Controlled Trial of Omega-3 and -6 Fatty Acid Supplementation to Reduce Inflammatory Markers in Children with Autism Spectrum Disorder.
Sarah A KeimAbigail JudeKatie SmithAiman Q KhanDaniel L CouryJoseph RauschShivika UdaipuriaMegan NorrisLindsay R BartramAnita R NarayananLynette K RogersPublished in: Journal of autism and developmental disorders (2022)
This double-blind, randomized controlled trial, tested fatty acid (FA) supplementation in children (ages 2- < 6 years) recently diagnosed with Autism Spectrum Disorder (ASD). Participants received daily oral FA supplement containing omega-3 and omega-6 FA, or a placebo for 90 days based on participant weight. Erythrocyte FAs and the cytokines, IL-1β, IL-2, IFNγ, were measured in plasma obtained from serial blood collections. Treatment increased omega-3 and omega-6 FA levels (1.40 mol% for EPA and 1.62 mol% for DHA) and reduced IL-2 levels compared to placebo (- 0.17 pg/mL, 95% CI - 0.31, - 0.02, d = - 0.62). Omega 3-6 treatment was tolerable and adherence was greater than 70%. Future research will assess the effects of Omega 3-6 treatment on ASD symptoms. Registered on 06/08/2018 with ClinicalTrials.gov: NCT03550209.
Keyphrases
- randomized controlled trial
- fatty acid
- autism spectrum disorder
- double blind
- study protocol
- clinical trial
- physical activity
- body mass index
- immune response
- systematic review
- type diabetes
- dendritic cells
- metabolic syndrome
- intellectual disability
- depressive symptoms
- weight loss
- phase iii
- combination therapy
- weight gain